Literature DB >> 26055304

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

M S Khodadoust1, B Luo1,2, B C Medeiros1, R C Johnson2, M D Ewalt2, A S Schalkwyk3, C D Bangs2, A M Cherry2, S Arai4, D A Arber2, J L Zehnder1,2, J Gotlib1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26055304      PMCID： PMC5369353          DOI： 10.1038/leu.2015.136

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Francis H Grand; Nicholas C P Cross
Journal:  Blood       Date:  2007-08-13       Impact factor: 22.113

2.  Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder.

Authors:  W Townsend; N C P Cross; K Waghorn; K Somana; A Ramsay; K Thomson; K Peggs
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

Review 3.  t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.

Authors:  Jad J Wakim; Carlos A Tirado; Weina Chen; Robert Collins
Journal:  Leuk Res       Date:  2011-05-31       Impact factor: 3.156

4.  Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.

Authors:  T Fioretos; I Panagopoulos; C Lassen; A Swedin; R Billström; M Isaksson; B Strömbeck; T Olofsson; F Mitelman; B Johansson
Journal:  Genes Chromosomes Cancer       Date:  2001-12       Impact factor: 5.006

5.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 6.  8p11 myeloproliferative syndrome: a review.

Authors:  Courtney C Jackson; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Hum Pathol       Date:  2010-04       Impact factor: 3.466

7.  Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.

Authors:  Anne Murati; Christine Arnoulet; Marina Lafage-Pochitaloff; José Adélaide; Martine Derré; Borhane Slama; Bénédicte Delaval; Cornel Popovici; Norbert Vey; Luc Xerri; Marie-Joelle Mozziconacci; Olivier Boulat; Danielle Sainty; Daniel Birnbaum; Max Chaffanet
Journal:  Int J Oncol       Date:  2005-06       Impact factor: 5.650

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.

Authors:  Satoshi Morishige; Eijiro Oku; Yuka Takata; Yoshizo Kimura; Fumiko Arakawa; Ritsuko Seki; Rie Imamura; Koichi Osaki; Michitoshi Hashiguchi; Kazuaki Yakushiji; Shinichi Mizuno; Koji Yoshimoto; Koji Nagafuji; Koichi Ohshima; Takashi Okamura
Journal:  Acta Haematol       Date:  2012-11-17       Impact factor: 2.195

10.  Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia.

Authors:  Karl Haslam; Stephen E Langabeer; Johanna Kelly; Natasha Coen; Niamh M O'Connell; Eibhlin Conneally
Journal:  Case Rep Hematol       Date:  2012-10-02
View more
  15 in total

1.  Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.

Authors:  Timothy Carll; Anand Patel; Benjamin Derman; Elizabeth Hyjek; Angela Lager; Pankhuri Wanjari; Jeremy Segal; Olatoyosi Odenike; Shiraz Fidai; Daniel Arber
Journal:  Blood Adv       Date:  2020-10-13

2.  FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Ying Liu; Xiaoli Mi; Ramya Gadde; Qi Gao; Wenbin Xiao; Yanming Zhang; Rayma Benayed; Maria Arcila; Ahmet Dogan; Mark B Geyer; Mikhail Roshal
Journal:  JCO Precis Oncol       Date:  2020-08-25

3.  Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.

Authors:  Tianxiang Hu; Yating Chong; Sumin Lu; Haiyan Qin; Mingqiang Ren; Natasha M Savage; Chang-Sheng Chang; John K Cowell
Journal:  Cancer Res       Date:  2018-11-09       Impact factor: 12.701

4.  Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.

Authors:  Marc Wehrli; Elisabeth Oppliger Leibundgut; Heinrich H Gattiker; Markus G Manz; Antonia M S Müller; Jeroen S Goede
Journal:  Oncologist       Date:  2017-02-27

5.  Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.

Authors:  John K Cowell; Haiyan Qin; Tianxiang Hu; Qing Wu; Aaron Bhole; Mingqiang Ren
Journal:  Int J Cancer       Date:  2017-07-28       Impact factor: 7.396

6.  DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.

Authors:  Tianxiang Hu; Yating Chong; Baohuan Cai; Yun Liu; Sumin Lu; John K Cowell
Journal:  J Biol Chem       Date:  2019-10-18       Impact factor: 5.157

7.  Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Nienke Zinger; Luuk Gras; Rodrigo Martino; Emmanouil Nikolousis; Jürgen Finke; Anabelle Chinea; Alessandro Rambaldi; Marie Robin; Riccardo Saccardi; Annalisa Natale; John A Snowden; Panagiotis Tsirigotis; Carlos Vallejo; Gerald Wulf; Blanca Xicoy; Domenico Russo; Johan Maertens; Etienne Daguindau; Stig Lenhoff; Patrick Hayden; Tomasz Czerw; Donal P McLornan; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2022-01-23       Impact factor: 5.174

8.  SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.

Authors:  Qing Wu; Aaron Bhole; Haiyan Qin; Judith Karp; Sami Malek; John K Cowell; Mingqiang Ren
Journal:  Oncotarget       Date:  2016-08-02

Review 9.  Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Authors:  Albert A Antolin; Paul Workman; Jordi Mestres; Bissan Al-Lazikani
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 10.  Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Authors:  Francesca Musumeci; Chiara Greco; Giancarlo Grossi; Alessio Molinari; Silvia Schenone
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.